Table 1. Baseline clinical characteristics and treatment response in all patients and in patients treated with R-CHOP and R-CHOEP.
| R-CHOP (n = 63) | R-CHOEP (n = 40) | TOTAL (n = 103) | p* | |||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |||
| Sex | F | 24 | 38 | 21 | 53 | 45 | 44 | 0.2 |
| M | 39 | 62 | 19 | 48 | 58 | 56 | ||
| Ann Arbor stage | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 0.6 |
| 2 | 2 | 3 | 3 | 8 | 5 | 5 | ||
| 3 | 26 | 41 | 17 | 43 | 43 | 42 | ||
| 4 | 32 | 51 | 20 | 50 | 52 | 50 | ||
| Performance status | 0–1 | 43 | 68 | 27 | 68 | 70 | 68 | 0.9 |
| 2–4 | 20 | 32 | 13 | 33 | 33 | 32 | ||
| aaIPI | 2 | 49 | 78 | 31 | 78 | 80 | 78 | 1.0 |
| 3 | 14 | 22 | 9 | 23 | 23 | 22 | ||
| LDH | Elevated | 60 | 95 | 39 | 98 | 99 | 96 | 0.6 |
| not elevated | 3 | 5 | 1 | 3 | 4 | 4 | ||
| Age ≤ 55 | 36 | 57 | 32 | 80 | 68 | 66 | 0.02 | |
| Age > 55 | 27 | 43 | 8 | 20 | 35 | 34 | ||
| Response evaluation | CR, Cru, PR | 47 | 75 | 35 | 88 | 82 | 80 | 0.3 |
| SD, PD | 9 | 14 | 3 | 8 | 12 | 12 | ||
| dead before evaluation | 5 | 8 | 1 | 3 | 6 | 6 | ||
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; F, female; M, male; aaIPI, age-adjusted international prognostic index; CR, complete remission; CRu, CR unconfirmed; PR, partial remission; SD, stable disease; PD, progressive disease; LDH, lactate dehydrogenase.
* p -Value: comparing R-CHOP to R-CHOEP.